These emerging therapies , Semaglutide , represent a significant advancement in addressing obesity and possibly associated ailments . These drugs are categorized as GLP-1 receptor agonists , indicating https://lilianfiwy649697.dsiblogger.com/74455652/tirzepatide-a-deep-dive-into-incretin-copyright